ArticleMolecular biology reports2026
Development of metformin-encapsulated poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThyroid cancer is a common endocrine malignancy. Conventional treatments, such as surgery, radioiodine therapy, radiotherapy, and chemotherapy, often result in significant side effects and toxicity. Nanoparticle-based drug delivery systems have emerged as a promising strategy to overcome these challenges. In this study, we investigated the effects of free metformin, a PLGA-PEG copolymer, and PLGA-PEG-MET nanoparticles on FTC-133 thyroid cancer cells. METHODS AND
resultsPLGA-PEG-MET nanoparticles were synthesized using the double-emulsion method and characterized using FT-IR and ZetaSizer. At the same time, drug loading was determined using a UV-Vis spectrophotometer. Drug-loading analysis showed the successful encapsulation of metformin within the nanoparticles. Colony formation assays revealed that both free metformin and PLGA-PEG-MET nanoparticles significantly reduced cell viability in a dose-dependent manner. Western blot analysis indicated that free metformin decreased mTOR expression while increasing AMPK and p-AMPK levels.
conclusionsThese findings suggest that PLGA-PEG-MET nanoparticles have potential as an effective therapeutic strategy for thyroid cancer. However, further studies are needed to enhance their effectiveness, both in vitro and in vivo. Additionally, the use of polymeric nanoparticle-based combination therapies may confer synergistic anticancer effects, as evidenced by improved therapeutic outcomes across various cancer types.
Indexed as
Identifiers
42207379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.